Effectiveness of BufferGel as a Vaginal Contraceptive – Full Text View

Effectiveness of BufferGel as a Vaginal Contraceptive - Full Text View

This is a single dose study that will evaluate the efficacy and safety of a Fixed Dose Combination Ibuprofen 250 mg/ Acetaminophen 500 mg tablet in healthy male patients with fever. Genital Herpes Clinical Research Trial Listings. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Carbopol 974P, the buffering agent in BufferGel, is a high molecular weight, cross-linked, polyacrylic acid used as a gelling or tableting agent in many pharmaceuticals; it has a well-documented record of mucosal safety in animals and humans. If the subject’s oral temperature is not between 97.4°F and 98.8°F, then 2 additional oral temperature readings will be obtained within a 30 minute period. Our lead candidate in genital herpes is GEN-003, a first-in-class, protein subunit T cell-enabled therapeutic vaccine, or immunotherapy, designed to reduce the.
Effectiveness of BufferGel as a Vaginal Contraceptive - Full Text View

Clinical trials database undergoes periodic update by dynamic process. MarketResearchReports.biz is the most comprehensive collection of market research reports. Participants will be followed through 6 menstrual cycles (approximately 7 months) and will have 4 study visits and one study phone call. Subjects with any gastrointestinal disorders (eg, gastrectomy, tracheostomy, esophageal surgeries, short gut syndrome, peptic ulcer disease, known or suspected obstructive disease, previous gastrointestinal surgery, felinization of the esophagus, hypomotility of the gastrointestinal track) that could affect the absorption, metabolism, or excretion of the study medication or affect the results of the ingestible thermometer. Facts About the HPV Vaccine Are You Having Safe Sex? Participants will be asked to keep a diary to record information on product use. Some participants may also be asked to enroll in a colposcopy substudy.

These participants will undergo colposcopy at study entry and after cycles 1, 3 and 6.

You may also like